

SOMETHING BETTER THAN HOPE

Overview of CIRM Policies and Procedures

March 23, 2021

CIRM's Mission

Accelerate stem cell
treatments to patients with
unmet medical needs.

Every Moment Counts | Don't Stop Now

2



How CIRM Gets Its Funds

Dr. Jonathan Thomas

March 23, 2021



1. Needs Assessment

The Team determines how much money CIRM will need in the ensuing six months to fund all anticipated programs and administrative expenses during that time period



2. Meeting with DOF

- Chair and Director of Finance meet semiannually with the Department of Finance in the Governor's office
- Present needs assessment and rationale
- DOF accepts or amends CIRM recommendations
- DOF informs the State Treasurer of its conclusions

+

•

3. State Treasurer Convenes Authorizing Committee

- The State Treasurer convenes the California Stem Cell Research and Cures Finance Committee Meeting (the “Committee”)
- The Committee includes the State Treasurer, representatives from the DOF and State Controller’s office plus the CIRM Chair, Vice Chair and additional CIRM Board member
- The Committee meets twice a year in advance of the State’s semiannual issuance of bonds/CP on behalf of State Agencies
- The Committee authorizes the issuance of CIRM’s bonds/CP in accordance with the DOF instructions

4. State Treasurer issues bonds/CP

- Following Committee authorization, the State Treasurer issues bonds/CP on behalf of CIRM
- Issuance is part of semiannual issuance on behalf of State agencies (spring and fall)
- Bond/CP proceeds are held in a segregated account by the State Controller



5. State Controller disburses funds

- CIRM money covers Big Bucket (projects) or Little Bucket (administrative) expenses
- CIRM notifies the State Controller each time it needs to disburse Big Bucket funds
- The State Controller disburses those Big Bucket funds directly to the specified recipient (e.g., grantee)
- The State Controller also disburses Small Bucket payments to pay vendors and to meet payroll for the CIRM Team. Funds are issued to vendors via a paper warrant upon receipt or a valid invoice or automatically under a prearranged disbursement schedule (such as direct deposit for monthly payroll)



6. Rinse and repeat

This process repeats itself every six months.

SOMETHING BETTER THAN HOPE

ICOC Subcommittees

Maria Bonneville

VP Administration
Executive Director to the Governing Board

March 23, 2021

CIRM
CALIFORNIA / STEM CELL AGENCY

ICOC Governing Board

35 Board Members

- Chair
- Vice-Chair
- 12 Patient Advocate Members
- 2 Nurses
- 15 Executive Officers from research institutions, medical schools and universities
- 4 California life-science commercial entity members

ICOC Meeting Schedule

- Full board meetings once a quarter
- Application Review Subcommittee (ARS) meetings once a month
- Remaining meetings for the year:
 - April – date TBD - ICOC
 - May 27th- ARS
 - June 28th - ICOC
 - July 20th - ARS
 - August 24th - ARS
 - September 23rd- ICOC
 - October 19th- ARS
 - November 23rd- ARS
 - December 14th - ICOC

ICOC Subcommittees

Today's Subcommittees

- Application Review Subcommittee
- Science Subcommittee
- Communication Subcommittee
- Legislative Subcommittee
- Governance Subcommittee
- Evaluation Subcommittee
- Transition Subcommittee
- Intellectual Property & Industry Engagement

Moving Forward

- Consolidate Evaluation and Governance
- Retire Legislative – matters will be brought straight to the board
- Retire Transition – no need for this any longer

Current Subcommittee Membership

Application Review Subcommittee	Communications Subcommittee	Evaluation Subcommittee	Finance Subcommittee	Governance Subcommittee
Dan Bernal	Ysabel Duron (Chair)	Stephen Juelsgaard (Co-Chair)	Stephen Juelsgaard (Chair)	Art Torres (Chair)
Anne-Marie Duliege	George Blumenthal	Judy Gasson (Co-Chair)	Judy Gasson	Al Rowlett
Ysabel Duron	Mark Fischer-Colbrie	Jonathan Thomas	Al Rowlett	Oswald Steward
Elena Flowers	Lawrence Goldstein	Art Torres	Suzanne Sandmeyer	Jonathan Thomas
David Higgins	Lauren Miller Rogen	Deborah Deas	Oswald Steward	Kristina Vuori
Steve Juelsgaard	Oswald Steward	Kristina Vuori	Jonathan Thomas	
David Martin	Jonathan Thomas		Art Torres	
Christine Miskowski			Kristina Vuori	
Lauren Miller Rogen				
Joe Panetta				
Adriana Padilla				
Al Rowlett				
Oswald Steward				
Jonathan Thomas				
Art Torres				
Karol Watson				
Diane Winokur				

Legislative Subcommittee	IP/Industry Subcommittee	Science Subcommittee	Transition Subcommittee
Art Torres (Chair)	Stephen Juelsgaard (Chair)	Oswald Steward (Chair)	Jonathan Thomas (Chair)
Linda Malkas	Anne-Marie Duliege	Deborah Deas	Judy Gasson
Joe Panetta	Joe Panetta	Anne-Marie Duliege	Steve Juelsgaard
Al Rowlett	Oswald Steward	Judy Gasson	Linda Malkas
Kristina Vuori	Jonathan Thomas	Lawrence Goldstein	Sholomo Melmed
		David Higgins	Joe Panetta
		Steve Juelsgaard	Al Rowlett
		Sholomo Melmed	Art Torres
		Art Torres	Kristina Vuori
		Jonathan Thomas	Diane Winokur
		Kristina Vuori	

Process for Appointment

ICOC Bylaws

The ICOC shall appoint the chairperson of each subcommittee based upon the recommendations of the members of the ICOC. The chairperson of the subcommittee shall then appoint the other members of the subcommittee with the concurrence of the Chairperson of the ICOC.

Once subcommittees are set, we will work on updating the mission and scope of each.

SOMETHING BETTER THAN HOPE

CIRM Grants Working Group

Gil Sambrano

Vice President
Portfolio Development and Review


March 23, 2021

CIRM
CALIFORNIA / STEM CELL AGENCY

What is the GWG?

- The CIRM Grants Working Group (GWG) is responsible for evaluating the scientific merit of all applications submitted to CIRM and to provide funding recommendations to the ICOC.
- The GWG is composed of:
 - 15 scientific members (not in California)
 - 7 patient advocate members of the ICOC
 - Chair of the ICOC, ex officio
- GWG panels are assembled and tailored with experts to evaluate proposals from specific funding opportunities such CLIN, TRAN, DISC.

Application Review Process



Merit Review:
GWG

Is the project scientifically meritorious?

- ✓ Does the project hold the necessary significance and potential for impact?
- ✓ Is the rationale sound?
- ✓ Is the project well planned and designed?
- ✓ Is the project feasible?
- ✓ Does the project address the needs of the underserved?

Merit Review:
GWG

GWG May Use a Two-Stage Review

- When the total number of applications exceeds the capacity of the GWG to review in a single session.
- In the first stage, GWG members including patient advocates conduct a pre-review of applications and select which ones to advance to a full review.
- The CIRM President and CIRM will examine non-selected applications to determine if any merit a full review. The remainder are not considered further.
- In the second stage, the GWG members review the selected applications in the usual manner, score, and make their funding recommendations to the ICOC.

GWG Scientific Scoring

Clinical Apps

GWG Scores:

- 1 Warrants funding
- 2 Needs improvement
- 3 Do not fund

Disc/Tran Apps

GWG Scores:

- 85+ Warrants funding
- <85 Do not fund

Funding Decision:
ICOC

Should CIRM fund the project?

- Application Review Subcommittee
- Occur monthly, mostly by teleconference
- Presentation of GWG recommendations
- Includes scores and summary of key strengths/weakness.
- Conducts Programmatic Review
- Vote to fund or not to fund



Funding Decision:
ICOC

Programmatic Review Considerations

- Scientific score and overall ranking of applications
- Alignment with CIRM mission and objectives of opportunity
- Potential impact of project to patients
- CIRM portfolio of projects
- DEI score
- Availability of funds



SOMETHING BETTER THAN HOPE

Review of CIRM Standards Working Group

Geoffrey Lomax, DrPH
Senior Science Officer

March 23, 2021




Scientific and Medical Standards Working Group (SWG)

- Recommend to the ICOC standards for:
 - Medical, socioeconomic, and financial aspects of clinical trials and therapy delivery to patients
 - Safe and ethical procedures for obtaining research materials (cells and tissue) & research consent
 - The oversight of funded research
- Composition:
 - ICOC chairperson and five patient advocates
 - Nine scientists and clinicians recognized in stem cell research
 - Four medical ethicists

SWG History: Phase 1 Oversight Framework for CIRM

2005 → 2007



Adopt National Academies Framework for Human Embryonic Stem Cell Research


- NAS Guidelines were adopted as state regulations covering all CIRM-funded research
- Fundamental Aim: Address "gaps" in federal regulations
- Major Impacts:
 - Creation of Stem Cell Research Oversight Committees
 - Robust informed consent for gamete and embryo research
 - Expanded hESC lines available to researchers

SWG History: Phase 2 Framework Validation

2008 → 2010



*Advancing the Effective Research Oversight:
2010 Regional Workshops on Regulatory
Compliance*



Workshop Summary
May 2010

Develop Good Practices Statewide for Stem Cell Research Oversight

- Facilitate grantees adoption of good oversight practices consistent with CIRM's policies
- Workshops attended by CIRM awardees
 - Shared implementation strategies
 - How Stem Cell Oversight Committees interact with IRBs
 - Recommendations to CIRM for enhancing effectiveness

**SOMETHING
BETTER
THAN HOPE**

CIRM
CALIFORNIA'S STEM CELL AGENCY

SWG History: Phase 3 iPSC Derivation and Banking

2011 → 2015

Ethical and Policy Considerations for A Pluripotent
Stem Cell Resource Center 2011 Update



Summary of the April 29, 2011 Annual meeting of the CIRM
Medical Accountability Standards Working Group

Los Angeles, California

June 28, 2011

www.CIRM.ca.gov

Establish Robust Education, Consent and Donation Protocol for CIRM's iPSC Bank


- Multiple CIRM SWG meeting to gather input from
 - Patients and families
 - Researchers and bio-bank administrators
 - Health / research communication experts
- CIRM Projects Outputs
 - Model informed consent for CIRM's iPSC Banking Initiative
 - Educational materials for prospective donors
 - Verification procedures to support use of iPSC lines

**SOMETHING
BETTER
THAN HOPE**

CIRM
CALIFORNIA'S STEM CELL AGENCY

SWG History: Current & Future Considerations Examples

2016 → Today



Genome Editing and Advance Treatments

- Endorsed NAS Statement on Genome Editing
- SWG 2016 Informed Consent Considerations for Embryo Genome Editing Studies

Potential Future Considerations

- Consent for clinical trials
- Embryo research
- Maintain vigilance on genetics research policy
- Permitted reimbursement

SOMETHING BETTER THAN HOPE

Review of CIRM Scientific and Medical Facilities Working Group

James Harrison

March 23, 2021



Scientific and Medical Facilities Working Group (FWG)

- Composition – 11 Members:
 - ICOC chairperson and six members of the GWG
 - Four California real estate specialists
- Functions – Recommend to the ICOC standards for:
 - Applications and awards for facilities funding for nonprofits institutions in California
 - Oversight of facilities awards
 - Review and recommend applications for facilities awards (Prop. 71 earmarked up to \$286.5 million for facilities)

History of Facilities Working Group

- Established in 2005
- Developed standards for application, award, and oversight of facilities funding to California nonprofit institutions
- Reviewed and recommended applications for Shared Labs Awards in 2007, with scientific merit of applications reviewed by GWG
 - Criteria included feasibility, cost, timeline, and institutional commitment
 - Funded 17 awards

History of Facilities Working Group

- Reviewed and recommended applications for Major Facilities Awards in 2007-2008, with scientific merit of applications reviewed by GWG
 - Criteria included urgency, value (excellence, innovation and costs), functionality, shared resources, and leverage
 - Levels of funding varied based on combination of uses
 - Institutes (discovery, translational, and clinical)
 - Centers of Excellence (two of three elements of research)
 - Special Programs (one element of research)

History of Facilities Working Group

- Funded 12 new research facilities in California at cost of \$271M (included facilities and research equipment)
 - CIRM Institutes
 - Sanford Consortium for Regenerative Medicine (Sanford Burnham, Salk, Scripps, and UCSD)
 - Stanford – Lorry Lokey Stem Cell Research Building
 - UCSF – Dolby Center for Regeneration Medicine Building
 - UCI – Gross Stem Cell Research Center
 - USC – Board CIRM Center for Regenerative Medicine and Stem Cell Research
 - UC Davis – Institute for Regenerative Medicine

History of Facilities Working Group

- CIRM Institutes
 - UCLA – Broad Center for Regenerative Medicine and Stem Cell Research
- CIRM Centers of Excellence
 - Buck Institute for Age Research
 - UC Berkeley – Stem Cell Center
- CIRM Special Programs
 - UC Santa Cruz – CIRM Institute for Biology of Stem Cells
 - UC Merced – Stem Cell Instrumentation Foundry
 - UC Santa Barbara – Center for Stem Cell Research and Engineering

History of Facilities Working Group

- Generated \$ 543M in matching funds, 13,000 job years, and \$100M in state tax revenues



FWG Future

- FWG has not met since 2010; needs to be reconstituted
- Functions – Recommend to the ICOC standards for:
 - Review and recommend applications for facilities awards programs established by Prop. 14
 - Shared Labs (up to \$26M)
 - Community Care Centers of Excellence (up to \$78M)

SOMETHING BETTER THAN HOPE

Board Policies

James Harrison
Counsel

March 23, 2021

CIRM
CALIFORNIA / STEM CELL AGENCY

CIRM Conflict of Interest Policies

CIRM Board Members Appointed Based on Expertise

- CIRM benefits from diverse expertise and experience of Board members
- Members are appointed to represent the interests of all Californians

Board Members are public officials for purposes of California conflict of interest laws

- Political Reform Act
- Form 700 and Attorney General Ethics Course
- Government Code Section 1090
- Common law conflicts of interest

CIRM Conflict Rules Go Further than State Law

- Members are precluded from participating in, or attempting to influence, a decision regarding an application submitted by their employer
- Members are precluded from applying for CIRM funding, acting as a PI on a CIRM application, or receiving salary support through a CIRM award
- Members are precluded from accepting a gift from any person or entity that does or seeks to do business with CIRM if gift is intended to influence or reward member for official action

CIRM Policies to Protect Against Appearance of Conflicts

- GWG scientific members are appointed from out-of-state
- Members are required to complete conflict verification before participating in consideration of applications
- CIRM team supplements conflict verification with review of Form 700s
- Programmatic review of applications conducted on blind basis
- Application Review Subcommittee makes all final funding decisions

Board Bylaws

- Define functions of Board
- Govern conduct of Board meetings
- Establish standing subcommittees and provide for establishment of additional subcommittees

Code of Conduct

- Establishes expectation that members regularly attend and actively participate in Board meetings and meetings of subcommittees of which they are members
- Requires Board members to protect the confidentiality of information provided to them as members of the Board, including in their capacity as members working groups or subcommittees
- Requires that requests for CIRM team to perform specific tasks be coordinated through Chair and President

Internal Governance Policy

- Defines responsibilities of Chair, Vice Chair, and President
- Provides for administrative and organizational structure of CIRM

SOMETHING BETTER THAN HOPE

Intellectual Property Regulations Summary

Benjamin Huang
Associate General Counsel

March 23, 2021

CIRM
CALIFORNIA / STEM CELL AGENCY

Proposition 71 Language (2004)

Section 125290.30 Public and Financial Accountability Standards

(h) Patent Royalties and License Revenues Paid to the State of California

The ICOC shall establish standards that require that all grants and loan awards be subject to intellectual property agreements that balance the opportunity of the State of California to benefit from the patents, royalties, and licenses that result from basic research, therapy development, and clinical trials with the need to assure that essential medical research is not unreasonably hindered by the intellectual property agreements. All revenues received through the intellectual property agreements established pursuant to this subdivision shall be deposited into the General Fund.

IP Regulations coverage

- Invention and Licensing Reporting to CIRM
- Publication Requirements
- Patent ownership
- Licensing and Assignment of CIRM-Funded Inventions and Technology
- Access Requirements for Products
- Revenue Sharing
- March-In Rights

Versions of the IP Regulations-(revenue sharing focus)

Initial 2006 version

- licensing revenue from patents for non-profits/for-profits
- royalty from for-profit self-commercialization

2009 version

- added CIRM-funded Technology licensing obligation (e.g. clinical data) as Disease Team program funding clinical research was launched

2014 version

- revised revenue sharing formula for non-profits
- changed the for-profit royalty formula

2018 version (current)

- changed the non-profit licensing formula into a royalty formula so all grantees are treated the same

Current revenue-sharing language

In Section 100650 Section VIII.(A), a royalty is calculated for the eventual Commercializing Entity to share with the State of California for deposit in the State's General Fund.

The first calculation is a royalty on Net Commercial Revenue at a rate of **0.1% per \$1 million** of CIRM Award for the earlier of 10 years from date of first sale or 9x of the grant amount. (For example, an Award totaling \$15 million will result in royalty payments of 1.5% of Net Commercial Revenues lasting until the earlier of 10 years after first sale or \$135 million deposited in the General Fund.)

In the event there is a CIRM-Funded Invention involved, the royalty requirements above are fulfilled, and the CIRM awards amounted to \$5 million or over, there is an additional 1% royalty on revenue in excess of \$500 million per year until the last-to-expire patent covering a CIRM-Funded Invention.

Proposition 14 Language (2020)

Section 125290.30 Public and Financial Accountability Standards

(j) Patent Royalties and License Revenues Paid to the State of California

*(1)The ICOC shall establish standards that require that all grants and loan awards be subject to intellectual property agreements that balance the opportunity of the State of California to benefit from the patents, royalties, and licenses that result from basic research, therapy development, and clinical trials with the need to assure that essential medical research is not unreasonably hindered by the intellectual property agreements. All royalty revenues received through the intellectual property agreements established pursuant to this subdivision shall be deposited into an interest-bearing account in the General Fund, **and to the extent permitted by law, the amount so deposited and interest thereon shall be appropriated for the purpose of offsetting the costs of providing treatments and cures arising from institute-funded research to California patients who have insufficient means to purchase such treatment or cure, including the reimbursement of patient-qualified costs for research participants.***

SOMETHING BETTER THAN HOPE

Board Self-Evaluation

James Harrison
Counsel

March 23, 2021


CIRM
CALIFORNIA / STEM CELL AGENCY

Background

- Survey sent to all Board members and alternates
- Last survey conducted in 2011
- Given board turnover and the expansion of the size of the Board, anticipated fewer responses than in 2011
- Survey results suggest interest in reinvigorating role of subcommittees, providing more input into development of Board agenda, and receiving more robust information regarding matters presented to the Board

Q1 CIRM Lives Up to Its Mission

Answered: 19 Skipped: 0




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	94.74%	18
NO	0.00%	0
SOMETIMES	5.26%	1
TOTAL		19

Q2 Board Focuses on the Appropriate Strategic, Fiduciary, and Oversight Issues that Guide the Work of CIRM

Answered: 18 Skipped: 1


ICOC Survey



ANSWER CHOICES	RESPONSES	
YES	88.99%	16
NO	5.56%	1
SOMETIMES	5.56%	1
TOTAL		18

Q3 Board Attends to Policy-Related Activities that Guide the Work of Management Staff

Answered: 18 Skipped: 1




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	83.33%	15
NO	0.00%	0
SOMETIMES	16.67%	3
TOTAL		18

Q4 Board Avoids Getting into Excessive Administrative/Management Details

Answered: 18 Skipped: 1




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	94.44%	17
NO	0.00%	0
SOMETIMES	5.56%	1
TOTAL		18

Q5 Board Engages in Appropriate Level of Oversight of CIRM Staff

Answered: 18 Skipped: 1




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	83.33%	15
NO	0.00%	0
SOMETIMES	16.67%	3
TOTAL		18

Q6 Board is Independent-Minded and Asks the Penetrating Questions Required to Uncover Issues

Answered: 19 Skipped: 0




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	89.47%	17
NO	0.00%	0
SOMETIMES	10.53%	2
TOTAL		19

Q7 Board Members Offer a Diversity of Opinions and Address Issues in a Respectful Manner

Answered: 19 Skipped: 0




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	100.00%	19
NO	0.00%	0
SOMETIMES	0.00%	0
TOTAL		19

Q8 Board's Level of Reliance on the Views of the President and/or Other Management Staff is Appropriate

Answered: 18 Skipped: 1




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	77.78%	14
NO	5.56%	1
SOMETIMES	16.67%	3
TOTAL		18

Q9 Board Plays an Appropriate Role in CIRM's Finances

Answered: 18 Skipped: 1




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	83.33%	15
NO	0.00%	0
SOMETIMES	16.67%	3
TOTAL		18

Q10 Board Makes Appropriate Use of Subcommittees to Provide Input/Recommendations

Answered: 18 Skipped: 1




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	66.67%	12
NO	11.11%	2
SOMETIMES	22.22%	4
TOTAL		18

Q11 Board Members Have Appropriate Input into the Preparation of the Agendas

Answered: 17 Skipped: 2


ICOC Survey



ANSWER CHOICES	RESPONSES	
YES	29.41%	5
NO	35.29%	6
SOMETIMES	35.29%	6
TOTAL		17

Q12 Board Meets with Appropriate Frequency and Timing to Carry Out its Mission

Answered: 18 Skipped: 1




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	94.44%	17
NO	5.56%	1
SOMETIMES	0.00%	0
TOTAL		18

Q13 Board Meeting are Conducted in a Manner that Ensures Open Communication and Meaningful Participation

Answered: 19 Skipped: 0




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	78.95%	15
NO	5.26%	1
SOMETIMES	15.79%	3
TOTAL		19

Q14 Board Grasps and Deliberates the Important Issues and Brings Decision Topics to Closure in a Timely Manner

Answered: 19 Skipped: 0

ICOC Survey




ANSWER CHOICES	RESPONSES	
YES	78.95%	15
NO	5.26%	1
SOMETIMES	15.79%	3
TOTAL		19

Q15 Board Receives Adequate Information to Understand the Issues Presented and to Make Good Decisions

Answered: 19 Skipped: 0

ICOC Survey




ANSWER CHOICES	RESPONSES	
YES	52.63%	10
NO	0.00%	0
SOMETIMES	47.37%	9
TOTAL		19

Q16 The Information Received Prior to and During the Meetings is Clear and Concise and is Delivered in a Timely Fashion

Answered: 19 Skipped: 0

ICOC Survey




ANSWER CHOICES	RESPONSES	
YES	68.42%	13
NO	5.26%	1
SOMETIMES	26.32%	5
TOTAL		19

Q17 Functionally, the Board has an Effective, Cooperative, and Collaborative Culture

Answered: 19 Skipped: 0


ICOC Survey



ANSWER CHOICES	RESPONSES	
YES	94.74%	18
NO	0.00%	0
SOMETIMES	5.26%	1
TOTAL		19

Q18 I Understand and Support CIRM's Mission

Answered: 19 Skipped: 0




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	100.00%	19
NO	0.00%	0
SOMETIMES	0.00%	0
TOTAL		19

Q19 I Understand My Responsibilities as a Board Member

Answered: 19 Skipped: 0




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	100.00%	19
NO	0.00%	0
SOMETIMES	0.00%	0
TOTAL		19

Q20 I Come to the Board Meetings Fully Prepared to Participate

Answered: 19 Skipped: 0




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	84.21%	16
NO	0.00%	0
SOMETIMES	15.79%	3
TOTAL		19

Q21 At Board Meetings, I feel Comfortable Raising and Discussing Dissenting or Contrary Opinions

Answered: 19 Skipped: 0


ICOC Survey



ANSWER CHOICES	RESPONSES	
YES	78.95%	15
NO	0.00%	0
SOMETIMES	21.05%	4
TOTAL		19

Q22 I Think About the Work of CIRM Between Board Calls and Meetings

Answered: 19 Skipped: 0




ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	68.42%	13
NO	0.00%	0
SOMETIMES	31.58%	6
TOTAL		19

Q23 I Understand the Issue of Conflict of Interest

Answered: 19 Skipped: 0


ICOC Survey



ANSWER CHOICES	RESPONSES	
YES	100.00%	19
NO	0.00%	0
SOMETIMES	0.00%	0
TOTAL		19

Q24 I Receive Personal Satisfaction from my Role as a Board Member

Answered: 19 Skipped: 0



ICOC Survey

ANSWER CHOICES	RESPONSES	
YES	100.00%	19
NO	0.00%	0
SOMETIMES	0.00%	0
TOTAL		19